Table 1.
Univariate analysis of symptomatic ischemic complication of the CNS.
| Characteristics | No ischemic complication (n = 111) | Symptomatic ischemic complication (n = 7) | P value |
|---|---|---|---|
| Median age (IQR) – years | 56 (47–63) | 54 (49–70) | 0.711 |
| Male gender (n, %) | 22 (19.8%) | 0 (0%) | 0.192 |
| Race & ethnicity (n, %) | 0.639 | ||
| African American | 24 (21.6%) | 3 (42.9%) | |
| Hispanic | 65 (58.6%) | 3 (42.9%) | |
| Asian | 6 (5.4%) | 0 (0%) | |
| Caucasian | 10 (9.1%) | 1 (14.3%) | |
| Other | 6 (5.4%) | 0 (0%) | |
| Median body mass index (IQR) | 28.3 (24.9–32.5) | 29.9 (24.8–30.3) | 0.882 |
| Prior history of SAH (n, %) | 24 (21.6%) | 2 (28.6%) | 0.667 |
| Family history of aneurysms (n, %) | 8 (7.2%) | 1 (14.3%) | 0.494 |
| Hypertension (n, %) | 62 (55.9%) | 6 (85.7%) | 0.121 |
| Diabetes (n, %) | 29 (26.1%) | 3 (42.9%) | 0.334 |
| Hyperlipidemia (n, %) | 39 (35.1%) | 4 (57.1%) | 0.241 |
| Cerebrovascular disease (n, %) | 18 (16.2%) | 4 (57.1%) | 0.007 |
| Coronary heart disease (n, %) | 5 (4.5%) | 0 (0%) | 0.566 |
| Alcohol use (n, %) | 24 (21.6%) | 3 (42.9%) | 0.195 |
| Smoking status (n, %) | 0.183 | ||
| Non-smoker | 54 (48.6%) | 2 (28.6%) | |
| Former smoker | 29 (26.1%) | 1 (14.3%) | |
| Current smoker | 28 (25.2%) | 4 (57.1%) | |
| Baseline mRS ≤ 2 (n, %) | 104 (93.7%) | 6 (85.7%) | 0.415 |
| Symptomatic presentation (n, %) | 60 (54.1%) | 2 (28.7%) | 0.190 |
| Mean no. of aneurysms (SD) | 1.6 ± 0.1 | 1.9 ± 0.3 | 0.524 |
| Mean no. of aneurysms treated (SD) | 1.1 ± 0.1 | 1.1 ± 0.2 | 0.753 |
| Aneurysm type – saccular (n, %) | 99 (89.1%) | 5 (71.4%) | 0.174 |
| Aneurysm location – anterior (n, %) | 98 (88.3%) | 6 (85.7%) | 0.783 |
| Median dome height (IQR) – mm | 5.9 (4.0-9.8) | 7.9 (5.5-10) | 0.592 |
| Median neck width (IQR) – mm | 3.8 (2.9-5.0) | 6.5 (5.3-7.0) | 0.017 |
| Median dome height to neck width ratio (IQR) | 1.6 (1.3-2.0) | 1.5 (0.8-1.6) | 0.168 |
| Stent type – pipeline (n, %) | 92 (82.8%) | 6 (85.7%) | 0.846 |
| Mean no. of stents (SD) | 1.4 ± 0.7 | 1.3 ± 0.4 | 0.636 |
| Median ADP % inhibition (IQR) | 73.0 (52.6–87.5) | 79.7 (52.3–95.1) | 0.420 |
| Clopidogrel resistance (n, %) | 21 (18.9%) | 1 (14.3%) | 0.752 |
| TEG Results | |||
| Median R time (IQR) – sec | 0.7 (0.5–0.8) | 0.7 (0.4–2.67) | 0.541 |
| Median K time (IQR) – sec | 3.2 (2.3–5.4) | 2.45 (1.60–2.85) | 0.114 |
| Median Alpha Angle (IQR) – deg | 60.3 (53.7–67.1) | 72.5 (63.7–75.8) | 0.013 |
| Median MA (IQR) – mm | 29.5 (17.3–42.2) | 52.3 (51.4–69.4) | 0.190 |
| Median LY30 (IQR) – percent | 0 (0–0) | 0 (0–0.1) | 0.591 |
CNS: central nervous system; IQR: interquartile range; SAH: subarachnoid hemorrhage; mRS: modified Rankin Scale; No.: number; SD: standard deviation; mm: millimeters; sec: seconds; deg: degrees; MA: maximum amplitude.